03.05.2016 21:15:00
|
Biogen Inc. -- Moody's: Biogen's hemophilia spin-off is credit negative
New York, May 03, 2016 -- Moody's Investors Service commented that the announcement by Biogen Inc. that it intends to spin-off its hemophilia business into an independent publicly traded company is credit negative. There is no impact on the company's Baa1 senior unsecured rating. The rating outlook remains negative.